Related Experiment Video
Updated: Jun 6, 2026

Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Lost in translation: neuropsychiatric drug development
Robert E Becker1, Nigel H Greig
1Aristea Translational Medicine Corporation, Freeport, ME 04078, USA. rebecker2008@comcast.net
Neuropsychiatric drug development faces critical flaws, including selective efficacy testing and ignoring practitioner needs. Improving clinical trials by incorporating basic science and clinical relevance is essential for valid and useful neurological and psychiatric drug research.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Recent studies highlight significant methodological and practical issues in neuropsychiatric drug development.
- These lapses can lead to data errors that invalidate clinical trial results and interpretations.
Purpose of the Study:
- To identify key sources of errors in neuropsychiatric drug development.
- To propose necessary changes to improve the validity and utility of clinical trials and drug development processes.
Main Methods:
- Analysis of identified method and practice lapses in neuropsychiatric drug development.
- Review of potential sources of difficulties, focusing on investigator practices.
Main Results:
- Two primary sources of problems identified: selective efficacy demonstration and failure to anticipate practitioner needs.
- Neglecting to test disease mechanism hypotheses in trials diminishes knowledge base credibility and scope.
- Failure to translate discoveries limits optimal patient care.
Conclusions:
- Clinical trials and drug development must integrate more basic science practices.
- Greater responsiveness to clinical practice conditions is crucial for improving neuropsychiatric drug studies.
- These changes are vital to address current threats to the validity and utility of neurological and psychiatric drug research.
More Related Videos
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
Related Concept Videos
Preclinical Development: Overview
Drug Therapy
Antianxiety Medications
Drugs Affecting Neurotransmitter Synthesis
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Clinical Trials: Overview
Psychosis: Goals of Pharmacotherapy